Since being forced into court receivership March 8, Korean ultrasound developer Medison had been seeking a white knight. But no more. The company best known for its pioneering efforts in 4D ultrasound has decided to stop looking for a corporate savior
Since being forced into court receivership March 8, Korean ultrasound developer Medison had been seeking a white knight. But no more. The company best known for its pioneering efforts in 4D ultrasound has decided to stop looking for a corporate savior and make it on its own. The company had attracted several suitors, including a number of foreign and domestic firms and a consortium. In each case, however, the proposed terms were too severe for Medison executives to accept, according to the company. In the meantime, the firm has divested itself of activities outside medical ultrasound and has posted strong sales revenue during this year's first half, leading to optimism that the company can succeed by itself.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.